8-K: NextCure Updates ADC Programs, Reports $41.8M Cash

NextCure, Inc. announced preliminary year-end 2025 cash of $41.8 million and provided updates on its SIM0505 and LNCB74 antibody drug conjugate programs, including a delay for LNCB74 proof-of-concept data.

Summary

• Preliminary cash, cash equivalents, and marketable securities totaled approximately $41.8 million as of December 31, 2025.
• Current financial resources are expected to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027.
• Data from the SIM0505 (CDH6 ADC) Phase 1 open-label dose escalation study are anticipated to be presented in the second quarter of 2026, including results from patients in the U.S. and China.
• The SIM0505 study is evaluating patients with advanced solid tumors, focusing on gynecological cancers and platinum-resistant ovarian cancer, with dose optimization expected to initiate in the first half of 2026.
• Dosing has commenced in higher dose cohorts for the ongoing LNCB74 (B7-H4 ADC) Phase 1 dose escalation study, prioritizing patients with high B7-H4 expression in breast and gynecological cancers, and now including adenoid cystic carcinoma type 1.
• Proof-of-concept data for LNCB74, previously anticipated in the first half of 2026, is delayed to the second half of 2026 to accommodate enrollment.

Sentiment

Score: 6

Explanation: The company reported a solid preliminary cash position and an extended runway into H1 2027, which provides stability. Progress on SIM0505 with data expected in Q2 2026 is a positive catalyst. However, the delay in LNCB74 proof-of-concept data due to enrollment issues introduces uncertainty and slightly dampens the overall sentiment. The inherent risks of clinical-stage biopharmaceutical development remain prominent.

Positives

• Reported a strong preliminary cash, cash equivalents, and marketable securities position of $41.8 million as of December 31, 2025.
• Extended cash runway into the first half of 2027, providing financial stability for ongoing operations and clinical development.
• SIM0505 Phase 1 data is expected in Q2 2026, combining U.S. and China results, which could provide a more comprehensive and definitive proof-of-concept.
• Expansion of SIM0505 clinical sites and increased drug supply are underway in anticipation of initiating dose optimization in the first half of 2026.
• LNCB74 Phase 1 dose escalation is progressing to higher dose cohorts and has expanded to include adenoid cystic carcinoma type 1, broadening its potential therapeutic scope.
• SIM0505 demonstrates approximately 10X stronger binding affinity to human CDH6 (EC50 of 0.028 nM) compared to an analog of DS-H01L02 (DS-6000 mAb intermediate) at 0.454 nM, suggesting improved selectivity.
• SIM0505's proprietary CPT116 TOPO1 inhibitor payload is designed for high systemic clearance and reduced toxicity, with no interstitial lung disease (ILD) reported in non-human primate (NHP) toxicology studies, differentiating it from competitors like DS-6000 which has reported ILD.
• LNCB74 utilizes a differentiated glucuronidase cleavable linker designed for improved safety and increased efficacy, aiming for a better therapeutic index compared to protease or esterase cleavable linkers used by some competitors.
• LNCB74 showed potent anti-tumor activity in OVCAR-3-B7-H4-OE (ovarian), CTG-0012 (TNBC PDX), and ZR-75-1 (breast) models, including 100% complete responses in the TNBC model at 6 mg/kg.

Negatives

• Proof-of-concept data for LNCB74 (B7-H4 ADC), previously anticipated in the first half of 2026, is delayed to the second half of 2026 due to the need to accommodate enrollment.
• The reported financial results are preliminary and unaudited, and therefore subject to adjustment.

Risks

• Positive results in preclinical studies may not be predictive of the results of clinical trials.
• Limited operating history and no products approved for commercial sale.
• History of significant losses.
• Need and ability to obtain additional financing on acceptable terms or at all.
• Risks related to clinical development, marketing approval, and commercialization, including risks associated with reliance upon collaborative partners and international vendors.
• Ability to maintain listing of common stock on the Nasdaq Global Select Market.
• Dependence on key personnel.
• The unproven approach to the discovery and development of product candidates based on NextCure's discovery platform.

Future Outlook

NextCure expects its current financial resources to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027. The company anticipates presenting SIM0505 Phase 1 data in Q2 2026 and providing a LNCB74 trial progress update in H2 2026, with SIM0505 dose optimization expected in H1 2026.

Management Comments

• NextCure is a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer.
• We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.

Industry Context

NextCure operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically within oncology and antibody-drug conjugates (ADCs). The focus on CDH6 and B7-H4 ADCs aligns with a broader industry trend towards targeted therapies for difficult-to-treat cancers, particularly gynecological and breast cancers. The delay in LNCB74 proof-of-concept data due to enrollment challenges is a common hurdle in clinical development, reflecting the complexities of patient recruitment for specialized trials.

Comparison to Industry Standards

• SIM0505 (CDH6 ADC) is compared to other CDH6 ADCs like DS-6000, CUSP06, HS-20124, and QLS-5133. SIM0505 shows approximately 10X stronger binding affinity to human CDH6 (EC50 of 0.028 nM) compared to an analog of DS-H01L02 (DS-6000 mAb intermediate) at 0.454 nM.
• SIM0505's proprietary CPT116 TOPO1 inhibitor payload is designed for high systemic clearance and reduced toxicity, with no ILD reported in NHP tox studies, contrasting with DS-6000 which has reported ILD, anemia, and neutropenia.
• LNCB74 (B7-H4 ADC) is compared to XMT-1660, HS-20089, AZD8205, and DB-1312/BG-C9074. LNCB74 uses a glucuronidase cleavable linker designed for improved safety and increased efficacy, aiming for a better therapeutic index compared to protease or esterase cleavable linkers used by some competitors.
• LNCB74 has shown potent anti-tumor activity in OVCAR-3-B7-H4-OE (ovarian), CTG-0012 (TNBC PDX), and ZR-75-1 (breast) models, including 100% complete responses in the TNBC model at 6 mg/kg.

Stakeholder Impact

• Shareholders: Potential for increased volatility due to clinical trial results and delays. The extended cash runway provides some reassurance regarding near-term dilution risk.
• Patients: Continued progress in ADC programs offers hope for new treatment options, particularly for advanced solid tumors and specific gynecological/breast cancers.
• Employees: Continued operations and program advancement support job stability and potential for future growth.
• Collaborative Partners (Simcere Zaiming, LigaChem Biosciences Inc): Ongoing collaboration and shared development efforts are critical for program success and future revenue sharing.

Next Steps

• Present SIM0505 Phase 1 open-label dose escalation study data in Q2 2026.
• Initiate SIM0505 dose optimization in the first half of 2026.
• Provide a LNCB74 trial progress update in the second half of 2026.
• Continue dosing patients in higher dose cohorts for the LNCB74 study.
• Finalize consolidated financial statements for the year ended December 31, 2025.

Key Dates

Recommendation

The company's preliminary cash position provides a solid runway into H1 2027, mitigating immediate financing concerns. The SIM0505 program shows promising preclinical differentiation and has an upcoming data readout in Q2 2026, which could be a significant catalyst. However, the delay in LNCB74 proof-of-concept data due to enrollment issues introduces uncertainty and suggests potential challenges in trial execution. Given the mixed news and the inherent high-risk nature of clinical-stage biopharmaceutical development, a 'hold' recommendation is appropriate until more definitive clinical data emerges from both programs.

Keywords

NextCure, NXTC, Biopharmaceutical, Cancer Therapy, Antibody Drug Conjugate, ADC, SIM0505, CDH6, LNCB74, B7-H4, Clinical Trials, Phase 1, Oncology, Ovarian Cancer, Breast Cancer, Adenoid Cystic Carcinoma, Cash Runway, SEC Filing, 8-K